Our findings emphasize the need for a better understanding of possible biological differences between pancreatic cancers that develop in patients with BRCA1 PVs vs BRCA2 PVs and consideration of stratification by mutation type in future clinical trials. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.